Springer Protocols: Abstract: 12. MRI in Preclinical Drug Development

12. MRI in Preclinical Drug Development

By: Matthew D. Silva², Sudeep Chandra³

Abstract

Full Text

Download PDF (493K)

This chapter outlines the challenges that the pharmaceutical industry faces during the course of drug development and discusses the role of magnetic resonance imaging in preclinical drug discovery.

Affiliation(s): (2) Department of Imaging Sciences, Millennium Pharmaceuticals Inc., Cambridge, MA
(3) Department of Imaging Sciences, Millennium Pharmaceuticals Inc., Cambridge, MA

Book Title: Magnetic Resonance Imaging: Methods and Biologic Applications

Series: Methods in Molecular Medicine | Volume: 124 | Pub. Date: Nov-01-2005 | Page Range: 299-322 | DOI: 10.1385/1-59745-010-3:299

Subject: Imaging/Radiology

Key Words: MRI - drug discovery - preclinical imaging

References

Download References

1.	http://www.phrma.org/issues/researchdev/.

2.	DiMasi J. A., Hansen R. W., and Grabowski H. G. (2003) The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151–185.

3.	DiMasi J. A., Hansen R. W., Grabowski H. G., and Lasagna L. (1991) Cost of innovation in the pharmaceutical industry. J. Health Econ. 10, 107–142.

4.	Roberts S. A. (2003) Drug metabolism and pharmacokinetics in drug discovery. Curr. Opin. Drug Discov. Devel. 6, 66–80.

5.	Franks R. and Hargeaves R. (2003) Clinical biomarkers in drug discovery and development. Nature Drug Discov. 2, 566–580.

6.	DiMasi J. A. (2002) The value of Imroving the productivity of the drug development process. Pharmacoeconomics 20 (Suppl. 3), 1–10.

7.	Beckmann N., Mueggler T., Allegrini P. R., Laurent D., and Rudin M. (2001) From anatomy to the target: contributions of magnetic resonance imaging to preclinical pharmaceutical research. Anat. Rec. 265, 85–100.

8.	Rudin M., Beckmann N., Porszasz R., Reese T., Bochelen D., and Sauter A. (1999) In vivo magnetic resonance methods in pharmaceutical research: current status and perspectives. NMR Biomed. 12, 69–97.

9.	Rudin M. and Weissleder R. (2003) Molecular imaging in drug discovery and development. Nat. Rev. Drug Discov. 2, 123–131.

10.	Weissleder R. and Mahmood U. (2001) Molecular imaging. Radiology 219, 316–333.

11.	Weissleder R. (2002) (Scaling down imaging: molecular mapping of cancer in mice). Nat. Rev. Cancer 2, 11–18.

12.	Chandra S., Clark L. V., Coatney R. W., Phan L., Sarkar S. K., and Ohlstein E. H. (1998) Application of serial in vivo magnetic resonance imaging to evaluate the efficacy of endothelin receptor antagonist SB 217242 in the rat carotid artery model of neointima formation. Circulation 97, 2252–2258.

13.	Chandra S., Sarkar S., Elliot J. D., and Ohlstein E. H. (1998) Application of magnetic resonance imaging for evaluation of the efficacy of SB 217242 in neointimal formation. J. Cardiovasc. Pharmacol. 31 (Suppl 1), 317–319.

14.	Beckmann N., Tigani B., Ekatodramis D., Borer R., Mazzoni L., and Fozard J. R. (2001) Pulmonary edema induced by allergen challenge in the rat: noninvasive assessment by magnetic resonance imaging. Magn. Reson. Med. 45, 88–95.

15.	Tigani B., Cannet C., Zurbrugg S., et al. (2003) Resolution of the oedema associated with allergic pulmonary inflammation in rats assessed noninvasively by magnetic resonance imaging. Br. J. Pharmacol. 140, 239–246.

16.	Hellings P. W., Hessel E. M., Van Den Oord J. J., Kasran A., Van Hecke, P., and Ceuppens J. L. (2001) Eosinophilic rhinitis accompanies the development of lower airway inflammation and hyper-reactivity in sensitized mice exposed to aerosolized allergen. Clin. Exp. Allergy. 31, 782–790.

17.	Middleton H., Black R. D., Saam B., et al. (1995) Magnetic Resonance Imaging with hyperpolarized 3He gas. Magn. Reson. Med. 33, 271–275.

18.	Samee S., Altes T., Powers P., et al. (2003). Imaging the lungs in asthmatic patients using hyperpolarized Helium-3 magnetic resonance assessment of response to methcholine exercise challenge. J. Allergy Clin. Immun. 111, 1205–1211.

19.	Waterton J. C., Rajanayagam V., Ross B. D., Whittemore A., and Johnstone D. (1993). Magnetic Resonance methods for measurement of disease progression in rheumatoid arthritis. Magn. Reson. Imaging 11, 1033–1038.

20.	Dawson J., Gustard S., and Beckmann N. (1999) High Resolution three dimensional magnetic resonance imaging for the investigation of knee joint damage during the time course of antigen induced arthiritis in rabbits. Arthritis Rheum. 42, 119–128.

21.	Beckmann N., Bruttel K., Mir A., and Rudin M. (1995) Non invasive 3D MR microscopy as a tool in pharmacological research: Applications to a model of arthritis. Magn. Reson. Imaging 13, 1013–1017.

22.	Beckmann N., Bruttel K., Schuurman H., and Mir A. (1998). Effects of sandimmune neural on collagen-induced arthritis in DA rats: Characterization by high resolution three dimensional magnetic resonance imaging and by histology. J. Magn. Reson. 131, 8–16.

23.	Beckmann N., Falk R., Zurbrugg S., Dawson J., and Engelhardt P. (2003) Macrophage infiltration into the rat knee detected by MRI in a model of antigeninduced arthritis. Magn. Reson. Med. 49, 1047–1055.

24.	Song S. K., Qu Z., Garabedian E. M., Gordon J. I., Milbrandt J., and Ackerman J. J. (2002) Improved magnetic resonance imaging detection of prostate cancer in a transgenic mouse model. Cancer Res. 62, 1555–1558.

25.	Fayad Z. A., Fallon J. T., Shinnar M., et al. (1998) Noninvasive In vivo high-resolution magnetic resonance imaging of atherosclerotic lesions in genetically engineered mice. Circulation 98, 1541–1547.

26.	Hockings P. D., Roberts T., Galloway G. J., et al. (2002) Repeated three-dimensional magnetic resonance imaging of atherosclerosis development in innominate arteries of low-density lipoprotein receptor-knockout mice. Circulation 106, 1716–1721.

27.	Fisher M. and Takano K. (1995) The penumbra, therapeutic time window and acute ischaemic stroke. Baillieres Clin. Neurol. 4, 279–295.

28.	Hoehn M., Nicolay K., Franke C., and van der Sanden B. (2001) Application of magnetic resonance to animal models of cerebral ischemia. J. Magn. Reson. Imaging 14, 491–509.

29.	Tatlisumak T. and Li F. (2003) Use of diffusion-and perfusion-weighted magnetic resonance imaging in drug development for ischemic stroke. Curr. Drug Targets CNS Neurol. Disord. 2, 131–141.

30.	Quast M. J., Huang N. C., Hillman G. R., and Kent T. A. (1993) The evolution of acute stroke recorded by multimodal magnetic resonance imaging. Magn. Reson. Imaging 11, 465–471.

31.	Hata R., Mies G., Wiessner C., et al. (1998) A reproducible model of middle cerebral artery occlusion in mice: hemodynamic, biochemical, and magnetic resonance imaging. J. Cereb. Blood Flow Metab. 18, 367–375.

32.	Baird A. E., Benfield A., Schlaug G., et al. (1997) Enlargement of human cerebral ischemic lesion volumes measured by diffusion-weighted magnetic resonance imaging. Ann. Neurol. 41, 581–589.

33.	Albers G. W. (1999) Expanding the window for thrombolytic therapy in acute stroke. The potential role of acute MRI for patient selection. Stroke. 30, 2230–2237.

34.	Guadagno J. V., Donnan G. A., Markus R., Gillard J. H., and Baron J. C. (2004) Imaging the ischaemic penumbra. Curr. Opin. Neurol. 17, 61–67.

35.	de Crespigny A. J., Tsuura M., Moseley M. E., and Kucharczyk J. (1993) Perfusion and diffusion MR imaging of thromboembolic stroke. J. Magn. Reson.Imaging 3, 746–754.

36.	Zhang Z., Zhang R. L., Jiang Q., Raman S. B., Cantwell L., and Chopp M. (1997) A new rat model of thrombotic focal cerebral ischemia. J. Cereb. Blood Flow Metab. 17, 123–135.

37.	Busch E., Kruger K., Allegrini P. R., et al. (1998) Reperfusion after thrombolytictherapy of embolic stroke in the rat: magnetic resonance and biochemical imaging. J. Cereb. Blood Flow Metab. 18, 407–418.

38.	Takano K., Carano R. A., Tatlisumak T., et al. (1998) Efficacy of intra-arterial and intravenous prourokinase in an embolic stroke model evaluated by diffusionperfusion magnetic resonance imaging. Neurology 50, 870–875.

39.	Jiang Q., Zhang R. L., Zhang Z. G., Ewing J. R., Divine G. W., and Chopp M. (1998) Diffusion-, T₂-, and perfusion-weighted nuclear magnetic resonance imaging of middle cerebral artery embolic stroke and recombinant tissue plasminogen activator intervention in the rat. J. Cereb. Blood Flow Metab. 18, 758–767.

40.	Gillies R. J., Bhujwalla Z. M., Evelhoch J., et al. (2000) Applications of Magnetic Resonance in Model Systems: Tumor Biology and Physiology. Neoplasia 2, 139–151.

41.	Weissleder R., Moore A., Mahmood U., et al. (2000) In vivo Magnetic Resonance Imaging of Transgene Expression, Nat. Med. 63, 351–354.

42.	Stegman L. D., Rehemetullah A., Beattle B., et al. (1999) Noninvasive quantitation of cytosine deaminase transgene expression in human tumor xenografts with in vivo magnetic resonance spectroscopy. Proc. Natl. Acad. Sci.US A 96, 9821–9826

43.	Nordsmark M., Maxwell R. J., Wood P. J., et al. (1996) Effects of hydralazine in spontaneous tumors assessed by oxygen electrodes and 31P magnetic resonance spectroscopy. Br. J.Cancer Suppl. 27, S232–235.

44.	Shine N., Palladino M. A., Patton J. S., et al. (1989) Early metabolic response to tumor necrosis factoring mouse sarcoma: a phophorus-31 nuclear magnetic resonance study. Cancer Res. 49, 2123–2127.

45.	Song S.-K., Qu Z., Garabedian E. M., Milbrandt J., and Ackerman J. J. (2002) Improved magnetic resonance imaging detection of prostate cancer in a transgenic mouse model. Cancer Res. 62, 1555–1558.

46.	Beckmann N. (2000) High resolution magnetic resonance angiography noninvasively reveals mouse strain differences in the cerebrovascular anatomy in vivo. Magn. Reson. Med. 44, 252–258.

47.	Chandra S., Willette R., Sauermelch C., et al. (1999) Angiographic Determination of Vessel Distensibility in vivo. Effects of Eprosartan (AII antagonist) in a severe Hypertension model. Proc. Int. Soc. Magn. Reson. Med. 7, 88.

48.	Kayyem J. F., Kumar R. M., Fraser S. E., and Meade T. J. (1995) Receptortargeted co-transport of DNA and magnetic resonance contrast agents. Chem. Biol. 2, 615–620.

49.	Louie A. Y., Huber M. M., Ahrens E. T., et al. (2000) In vivo visualization of gene expression using magnetic resonance imaging. Nat. Biotechnol. 18, 321–325.

50.	Hogemann D., Ntziachristos V., Josephson L., and Weissleder R. (2002) High throughput magnetic resonance imaging for evaluating targeted nanoparticle probes. Bioconjugate Chem. 13, 116–121.

51.	Roussel S. A., van Bruggen N., King M. D., Houseman J., Williams S. R., and Gadian D. G. (1994) Monitoring the initial expansion of focal ischaemic changes by diffusion-weighted MRI using a remote controlled method of occlusion. NMR Biomed. 7, 21–28.

52.	Li F., Han S., Tatlisumak T., et al. (1998) A new method to improve in-bore middle cerebral artery occlusion in rats: demonstration with diffusion-and perfusion-weighted imaging. Stroke 29, 1715–1719.

53.	Ishikawa S., Yokoyama K., Kuroiwa T., and Makita K. (2001) Evolution of cerebral ischaemia induced by thromboembolism in rats detected by early sequential MR imaging. Br. J. Anaesth. 87, 469–476.

54.	Gerriets T., Li F., Silva M. D., et al. (2003) The macrosphere model: evaluation of a new stroke model for permanent middle cerebral artery occlusion in rats. J. Neurosci. Methods 122, 201–211.

55.	Kudo M., Aoyama A., Ichimori S., and Fukunaga N. (1982) An animal model of cerebral infarction. Homologous blood clot emboli in rats. Stroke 13, 505–508.

56.	Koizumi J., Yoshida Y., Nakazawa T., and Ooneda G. (1986) Experimental studies of ischemic brain edema, I: a new experimental model of cerebral embolism in rats in which recirculation can be introduced in the ischemic area. Jpn. J. Stroke 8, 1–8.

57.	Sauter A. and Rudin M. (1986) Calcium antagonists reduce the extent of infarction in rat middle cerebral artery occlusion model as determined by quantitative magnetic resonance imaging. Stroke 17, 1228–1234.

58.	Sauter A., Rudin M., and Wiederhold K. H. (1988) Reduction of neural damage in irreversible cerebral ischemia by calcium antagonists. Neurochem. Pathol. 9, 211–236.

59.	Chandra S., White R. F., Everding D., et al. (1999) Use of diffusion-weighted MRI and neurological deficit scores to demonstrate beneficial effects of isradipine in a rat model of focal ischemia. Pharmacology 58, 292–299.

60.	Reese T., Porszasz R., Baumann D., et al. (2000) Cytoprotection does not preserve brain functionality in rats during the acute post-stroke phase despite evidence of non-infarction provided by MRI. NMR Biomed. 13, 361–370.

61.	Germano I. M., Bartkowski H. M., Berry I., Moseley M., Brant-Zawadzki M., and Pitts L. H. (1986) Magnetic resonance imaging in the evaluation of nimodipine-treated acute experimental focal cerebral ischemia. Acta Radiol. Suppl. 369, 49–52.

62.	Kucharczyk J., Chew W., Derugin N., et al. (1989) Nicardipine reduces ischemic brain injury. Magnetic resonance imaging/spectroscopy study in cats. Stroke 20, 268–274.

63.	Chew W., Kucharczyk J., Moseley M., Derugin N., and Norman D. (1991) Hyperglycemia augments ischemic brain injury: in vivo MR imaging/spectroscopic study with nicardipine in cats with occluded middle cerebral arteries. AJNR Am. J. Neuroradiol. 12, 603–609.

64.	Yenari M. A., Palmer J. T., Sun G. H., de Crespigny A., Mosely M. E., and Steinberg G. K. (1996) Time-course and treatment response with SNX-111, an N-type calcium channel blocker, in a rodent model of focal cerebral ischemia using diffusion-weighted MRI. Brain Res. 739, 36–45.

65.	Perez-Pinzon M. A., Yenari M. A., Sun G. H., Kunis D. M., and Steinberg G. K. (1997) SNX-111, a novel, presynaptic N-type calcium channel antagonist, is neuroprotective against focal cerebral ischemia in rabbits. J. Neurol. Sci. 153,25–31.

66.	Seega J. and Elger B. (1993) Diffusion-and T₂-weighted imaging: evaluation of oedema reduction in focal cerebral ischaemia by the calcium and serotonin antagonist levemopamil. Magn. Reson. Imaging 11, 401–409.

67.	Reggiani A., Pietra C., Arban R., et al. (2001) The neuroprotective activity of the glycine receptor antagonist GV150526: an in vivo study by magnetic resonance imaging. Eur. J. Pharmacol. 419, 147–153.

68.	Petty M. A., Neumann-Haefelin C., Kalisch J., Sarhan S., Wettstein J. G., and Juretschke H. P. (2003) In vivo neuroprotective effects of ACEA 1021 confirmed by magnetic resonance imaging in ischemic stroke. Eur. J. Pharmacol. 474, 53–62.

69.	Takano K., Tatlisumak T., Formato J. E., et al. (1997) Glycine site antagonist attenuates infarct size in experimental focal ischemia. Postmortem and diffusion mapping studies. Stroke 28, 1255–1262.

70.	Qiu H., Hedlund L. W., Gewalt S. L., Benveniste H., Bare T. M., and Johnson G. A. (1997) Progression of a focal ischemic lesion in rat brain during treatment with a novel glycine/NMDA antagonist: an in vivo three-dimensional diffusionweighted MR microscopy study. J. Magn. Reson. Imaging 7, 739–744.

71.	Lo E. H., Pierce A. R., Mandeville J. B., and Rosen, B. R. (1997) Neuroprotection with NBQX in rat focal cerebral ischemia. Effects on ADC probability distribution functions and diffusion-perfusion relationships. Stroke 28, 439–446.

72.	Kucharczyk, J., Mintorovich, J., Sevick, R., Asgari H., and Moseley M. (1990) MR evaluation of calcium entry blockers with putative cerebroprotective effects in acute cerebral ischaemia. Acta Neurochir. Suppl. (Wien). 51, 254–255.

73.	Li F., Carano R. A., Irie K., et al. (1999) Neuroprotective effects of a novel broad-spectrum cation channel blocker, LOE 908 MS, on experimental focal ischemia: a multispectral study.J. Magn. Reson. Imaging 10, 138–145.

74.	Allegrini P. R. and Sauer D. (1992) Application of magnetic resonance imaging to the measurement of neurodegeneration in rat brain: MRI data correlate strongly with histology and enzymatic analysis. Magn. Reson. Imaging 10, 773–778.

75.	Pschorn U., Korperich H., Heymans L., Subramanian S., and Kuhn W. (1993) MRI and MRS studies on the time course of rat brain lesions and the effect of drug treatment: volume quantification and characterization of tissue heterogeneity by parameter selection.Magn. Reson. Med. 30, 174–182.

76.	Sauer D., Martin P., Allegrini P. R., Bernasconi R., Amacker H., and Fagg G. E. (1992) Differing effects of alpha-difluoromethylornithine and CGP 40116 on polyamine levels and infarct volume in a rat model of focal cerebral ischaemia. Neurosci. Lett. 141, 131–135.

77.	Sauer D., Allegrini P. R., Cosenti A., Pataki A., Amacker H., and Fagg G. E. (1993) Characterization of the cerebroprotective efficacy of the competitive NMDA receptor antagonist CGP40116 in a rat model of focal cerebral ischemia: an in vivo magnetic resonance imaging study.J. Cereb. Blood Flow Metab. 13, 595–602.

78.	Minematsu K., Fisher M., Li L., et al. (1993) Effects of a novel NMDA antagonist on experimental stroke rapidly and quantitatively assessed by diffusionweighted MRI.Neurology 43, 397–403.

79.	Minematsu K., Fisher M., Li L., and Sotak C. H. (1993) Diffusion and perfusion magnetic resonance imaging studies to evaluate a noncompetitive N-methyl-D-aspartate antagonist and reperfusion in experimental stroke in rats. Stroke 24, 2074–2081.

80.	Perez-Pinzon M. A., Maier C. M., Yoon E. J., Sun G. H., Giffard R. G., and Steinberg G. K. (1995) Correlation of CGS 19755 neuroprotection against in vitro excitotoxicity and focal cerebral ischemia. J. Cereb. Blood Flow Metab. 15, 865–876.

81.	Bochelen D., Rudin M., and Sauter A. (1999) Calcineurin inhibitors FK506 and SDZ ASM 981 alleviate the outcome of focal cerebral ischemic/reperfusion injury. J. Pharmacol. Exp. Ther. 288, 653–659.

82.	Kozniewska E., Roberts T. P., Tsuura M., Mintorovitch J., Moseley M. E., and Kucharczyk J. (1995) NG-nitro-L-arginine delays the development of brain injury during focal ischemia in rats. Stroke 26, 282–288.

83.	Quast M. J., Wei J., and Huang N. C. (1995) Nitric oxide synthase inhibitor NGnitro-L-arginine methyl ester decreases ischemic damage in reversible focal cerebral ischemia in hyperglycemic rats. Brain Res. 677, 204–212.

84.	Haga K. K., Gregory L. J., Hicks C. A., et al. (2003) The neuronal nitric oxide synthase inhibitor, TRIM, as a neuroprotective agent: effects in models of cerebral ischaemia using histological and magnetic resonance imaging techniques. Brain Res. 993, 42–53.

85.	Lee J. H., Lee Y. K., Ishikawa M., et al. (2003) Cilostazol reduces brain lesion induced by focal cerebral ischemia in rats-an MRI study.Brain Res. 994, 91–98.

86.	Lesiuk H., Sutherland G., Peeling J., Butler K., and Saunders J. (1991) Effect of U74006F on forebrain ischemia in rats. Stroke 22, 896–901.

87.	Muller T. B., Haraldseth O., Jones R. A., et al. (1995) Perfusion and diffusionweighted MR imaging for in vivo evaluation of treatment with U74389G in a rat stroke model. Stroke 26, 1453–1458.

88.	Imura Y., Kiyota Y., Nagai Y., Nishikawa K., and Terashita Z. (1995) Beneficial effect of CV-4151 (Isbogrel), a thromboxane A2 synthase inhibitor, in a rat middle cerebral artery thrombosis model. Thromb. Res. 79, 95–107.

89.	Tatlisumak T., Takano K., Carano R. A., and Fisher M. (1996) Effect of basic fibroblast growth factor on experimental focal ischemia studied by diffusionweighted and perfusion imaging. Stroke 27, 2292–2297.

90.	van Bruggen N., Thibodeaux H., Palmer J. T., et al. (1999) VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain. J. Clin. Invest. 104, 1613–1620.

91.	Kent T. A., Quast M., Taglialatela G., et al. (1999) Effect of NGF treatment on outcome measures in a rat model of middle cerebral artery occlusion. J. Neurosci. Res. 55, 357–369.